Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 17;14(11):2540.
doi: 10.3390/v14112540.

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir

Karolina Akinosoglou  1 , Georgios Schinas  1 , Charalambos Gogos  1
Affiliations
Review

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir

Karolina Akinosoglou et al. Viruses. .

Abstract

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to confine the pandemic and treat infected individuals on an outpatient basis has led to the approval of oral antiviral agents. Taking into account the viral kinetic pattern of SARS-CoV-2, it is of high importance to intervene at the early stages of the disease. A protease inhibitor called nirmatrelvir coupled with ritonavir (NMV/r), which acts as a CYP3A inhibitor, delivered as an oral formulation, has shown much promise in preventing disease progression in high-risk patients with no need for supplemental oxygen administration. Real-world data seem to confirm the drug combination's efficacy and safety against all viral variants of concern in adult populations. Although, not fully clarified, viral rebound and recurrence of COVID-19 symptoms have been described following treatment; however, more data on potential resistance issues concerning the Mpro gene, which acts as the drug's therapeutic target, are needed. NMV/r has been a gamechanger in the fight against the pandemic by preventing hospitalizations and halting disease severity; therefore, more research on future development and greater awareness on its use are warranted.

Keywords: COVID-19; Paxlovid; SARS-CoV-2; nirmatrelvir; nirmatrelvir/ritonavir; ritonavir; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Protease inhibitors (PIs) evolution.
Figure 2
Figure 2
Algorithm on potential drug–drug interactions of nirmatrelvir/ritonavir.
See this image and copyright information in PMC

References

    1. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med. J. 2021;97:312–320. doi: 10.1136/postgradmedj-2020-138577. - DOI - PMC - PubMed
    1. Estiri H., Strasser Z.H., Murphy S.N. Individualized prediction of COVID-19 adverse outcomes with MLHO. Sci. Rep. 2021;11:5322. doi: 10.1038/s41598-021-84781-x. - DOI - PMC - PubMed
    1. Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830. - DOI - PMC - PubMed
    1. NIH COVID-19 Treatment Guidelines. [(accessed on 1 November 2022)]; Available online: https://www.covid19treatmentguidelines.nih.gov/management/clinical-manag...
    1. European Centre for Disease Prevention and Control 2022 High-Risk Groups for COVID-19. [(accessed on 5 November 2022)]. Available online: www.ecdc.europa.eu/en/covid-19/high-risk-groups.

LinkOut - more resources